Logo
SubscribeSign In
LeaderPortfolio
Billionaire Profile
Barbara Boehringer
Global Rank
#650

Image: Public domain | via Wikimedia Commons

Barbara Boehringer

CEO, Boehringer Ingelheim
DE
Real-Time Net Worth
$5.7B
As of December 2025
Age
53
Source
Pharmaceuticals
Industry
healthcare
Citizenship
DE

Biography

Barbara Boehringer, at 53 years old, is a prominent figure in the pharmaceutical industry, with a net worth estimated at $5.7 billion. Her wealth stems from her inheritance within the Boehringer Ingelheim family, the world's largest privately-owned pharmaceutical company. Her career has been influenced by the legacy of her family's enterprise, contributing to a global workforce of over 53,000 employees in 130 markets. Boehringer Ingelheim is recognized for innovative drugs treating conditions like COPD, anti-coagulation, and type 2 diabetes.

Wealth Over Time

In-Depth Profile

Early Life

Barbara Boehringer is part of the Boehringer Ingelheim family, a German dynasty with deep roots in the pharmaceutical industry. The company was founded in 1885 by Albert Boehringer, who started with a small factory producing ingredients for pharmacies. The family has been involved in the business for multiple generations.

Rise to Success

Boehringer Ingelheim grew from a modest chemical factory to a global enterprise. The company's success can be attributed to its dedication to research, development, and the manufacturing of innovative healthcare products. The company's ability to remain privately owned has allowed it to focus on long-term goals and breakthroughs that have transformed patients' lives.

Key Business Strategies

Boehringer Ingelheim is a research-driven company with a strong focus on innovation in both Human Pharma and Animal Health. The company invests heavily in research and development. In 2023, R&D investments were approximately EUR 6.2 billion.

Philanthropy

Boehringer Ingelheim is involved in philanthropic initiatives. For example, the company supports stroke care through the Angels Initiative. The company also supports research. The company has also invested in initiatives to improve the well-being of animals.